A Prospective Study on Clinical and Echocardiographic Outcomes of Percutaneous Transvenous Mitral Commissurotomy (PTMC) in Patients with Isolated Rheumatic Mitral Stenosis

Background: Mitral Stenosis (MS) is the most common valve lesion in chronic rheumatic heart disease (RHD). Percutaneous Transvenous Mitral Commissurotomy (PTMC) has emerged as an alternative to surgical intervention for the management of patients with isolated rheumatic MS. The aim of this study was to assess the clinical and echocardiographic outcomes of Percutaneous Transvenous Mitral Commissurotomy (PTMC) in patients with isolated rheumatic mitral stenosis. Material & Methods: This prospective observational study was conducted in Department of Cardiology of National Institute of Cardiovascular Diseases (NICVD), Dhaka, Bangladesh, during the period from May 2019 to April 2020 for a period of one (01) year. Total 30 patients with moderate to severe MS due to chronic rheumatic heart disease undergoing PTMC were included in this study. Results: In this study of 30 patients undergoing PTMC, the majority were aged 30-39 years (40%), with a mean age of 32.7 years. Females predominated (63.3%), with a female-to-male ratio of 1.7:1. Most patients were of normal weight (63.3%), with a mean BMI of 20.8 kg/m2. The severity of heart failure, assessed by NYHA class, was highest in class III (56.7%). Echocardiographic improvements post-PTMC were significant, with notable correlations between GLS and other cardiac parameters. Conclusions: This present study concludes that PTMC is a vital intervention in managing mitral stenosis, particularly in terms of functional improvement and symptom relief. The clinical and echocardiographic outcomes advocate for the continued use of PTMC as a key therapeutic strategy in suitable patients with mitral stenosis.